Amarin to Present at UBS Life Sciences Conference
DUBLIN and MYSTIC, Conn., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present on Amarin's behalf at the Global UBS Life Sciences Conference on Wednesday, September 22, 2010 at 12:30 pm. This conference will be held at the Grand Hyatt New York in New York City. Colin Stewart, recently appointed as President and Chief Executive Officer, will also be at the conference representing Amarin in meetings with investors.
A live audio webcast of the presentation will be available at the following URL:
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia on statin therapy. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts: Investor Contact Information: John F. Thero Chief Financial Officer In US: +1 (860) 572 4979 firstname.lastname@example.org Lee M. Stern The Trout Group In U.S. +1 (646) 378-2922 email@example.com International Media Contact Information: Mark Swallow or David Dible Citigate Dewe Rogerson In UK: +44 (0)207 638 9571 firstname.lastname@example.org
SOURCE Amarin Corporation plc
Copyright (C) 2010 PR Newswire. All rights reserved